Search results for #TransThera
Tinengotinib VS. Physician's Choice for Patients With FGFR-altered Cholangiocarcinoma (FIRST-308) classic.clinicaltrials.gov/ct2/show/NCT05… First phase 3 trial: FGFR-inhibitor refractory CCA open! @curecc @CrainesCrew @melinda_bachini @MDAndersonNews @CharityAMMF @CcaEns #TransThera #livertwitter
THANK YOU! AMMF thanks @AstraZeneca,@Incyte, @HelsinnGroup @Servier, @TaihoOncology, #TransThera and @ZymeworksInc for their support for AMMF’s Hybrid CCA Conference during 11–13 May 2022! #AMMF2022 #LiverTwitter #cholangiocarcinoma
#TransThera Announces that the #InvestigationalNewDrug Application of #TT01488, a Non-covalent Reversible #BTKInhibitor, for the Treatment of #BCellLymphomas has been Approved by the #FDA in the US and Officially Accepted by the #NMPA in China 1stoncology.com/blog/transther…
#TransThera Receives #FastTrackDesignation from FDA for its Core Product #TT00420 to Treat #Cholangiocarcinoma 1stoncology.com/blog/transther…
LG Chem Life Sciences and #TransThera Biosciences Announce License Agreement for Potential Treatment of NASH and Other Chronic Inflammatory Conditions alshaminfo.com/story-z16835854
FDA approves TransThera’s IND for TT-00920 to treat heart failure READ: reportsgo.com/fda-approves-t…, #FDA, #HeartFailure , #IND, #Transthera, #healthcare, #pharmacokinetics, #CHF #HFpEF
[#ChronicHeart Failure Treatment] #TransThera Biosciences Co. Ltd, a clinical-stage #biotechnology company based in #China, announced today that the U.S. #FDA has granted the company’s Investigational #NewDrug (IND) application for TT-00920. nai500.com/blog/2019/12/t…
